Clinical Trial Update: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of oral rigosertib in transfusion-dependent myelodysplastic syndrome, including lower- and intermediate-risk ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndrome, MDS | Phase 2 | Status: COMPLETED